Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alimera Sciences, Inc. (NASDAQ: ALIM).

Full DD Report for ALIM

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALIM)

Alimera Sciences' (ALIM) CEO Dan Myers on Q1 2018 Results - Earnings Call Transcript
Alimera Sciences, Inc. (ALIM) Q1 2018 Results Earnings Conference Call May 3, 2018, 10:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - CEO Rick Eiswirth - President and CFO Analysts Andrew D'Silva - B. Riley FBR François Brisebois - Laidlaw & Compan...
Source: SeekingAlpha
Date: May, 06 2018 07:19
Alimera Sciences, Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 04 2018 13:55
Alimera Sciences Reports First Quarter 2018 Results
Net Revenue in Q1 of 2018 increased 48% over Q1 of 2017 U.S. Net Revenue increased 59% in Q1 of 2018 over Q1 of 2017 International Revenue in Q1 of 2018 increased 27% over Q1 of 2017 End User Demand in the U.S. was up 21% over Q1 of 2017 ATLANTA, GA / ACCESSWIRE...
Source: ACCESSWIRE
Date: May, 02 2018 16:15
Alimera Sciences to Report First Quarter 2018 Results May 2, 2018
ATLANTA, GA / ACCESSWIRE / April 24, 2018 / Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the first quarter ended March 31, 2018, after the close of...
Source: ACCESSWIRE
Date: April, 24 2018 16:30
Alimera Sciences Announces Data from 19 Iluvien(R) Studies to be Presented at 2018 ARVO
ATLANTA, GA / ACCESSWIRE / April 24, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that data from 19 ILUVIEN pivotal and post-marketing studies have been accepted for presentat...
Source: ACCESSWIRE
Date: April, 24 2018 07:30
FDA OKs AI software to detect diabetic retinopathy
Under its De Novo (no predicate product) review pathway, the FDA approves the first medical device in the U.S. that uses artificial intelligence (AI) to perform its designated function. The device, called IDx-DR, is a software program used to detect greater than a mild level of diabetic re...
Source: SeekingAlpha
Date: April, 11 2018 12:51
Alimera Sciences' (ALIM) CEO Dan Myers on Q4 2017 Results - Earnings Call Transcript
Alimera Sciences, Inc. (ALIM) Q4 2017 Earnings Conference Call March 1, 2018 9:00 A.M. ET Executives Jacob Goldberger - CG Capital Dan Myers - Chief Executive Officer Rick Eiswirth - President and Chief Financial Officer Analysts François Brisebois - Laidlaw & Comp...
Source: SeekingAlpha
Date: March, 01 2018 12:48
Alimera Sciences misses by $0.06, misses on revenue
Alimera Sciences (NASDAQ: ALIM ): Q4 EPS of -$0.10 misses by $0.06 . Revenue of $9.14M (-14.4% Y/Y) misses by $3.03M . Press Release More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: February, 28 2018 16:32
Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results
GAAP Net Loss cut by 34% from $33.2 in 2016 to $22.0 million in 2017 Adjusted EBITDA loss reduced by 61% from $22.8 million in 2016 to $8.8 million 2017 Filed for Type II variation for uveitis in Europe for ILUVIEN in Q4 of 2017 Refinanced previous debt facility with new debt fac...
Source: GlobeNewswire
Date: February, 28 2018 16:30
Alimera Sciences to Present at the 38th Annual Cowen & Co. Health Care Conference
ATLANTA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will present at the 38 th Annual Cowen & Co....
Source: GlobeNewswire
Date: February, 27 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-130.950.91311.01040.85233,010
2018-08-090.87810.87480.890.85101,087
2018-08-080.77010.86040.890.75366,278
2018-08-070.820.790.9280.79123,250
2018-08-060.930.85070.930.85200,748

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1349,39876,46464.6030Short
2018-08-1022,32376,43929.2037Cover
2018-08-0946,37878,55359.0404Short
2018-08-08136,054268,37550.6955Short
2018-08-0752,04781,49163.8684Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALIM.


About Alimera Sciences, Inc. (NASDAQ: ALIM)

Logo for Alimera Sciences, Inc. (NASDAQ: ALIM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ALIM)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: March, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 09 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 28 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: ALIM)

      Daily Technical Chart for (NASDAQ: ALIM)


      Stay tuned for daily updates and more on (NASDAQ: ALIM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ALIM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALIM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALIM and does not buy, sell, or trade any shares of ALIM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/